Resultados de Búsqueda por Autor

artículo

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Publicado por
Sharma, P, López-Tarruella, S, García-Saenz, JA, Khan, QJ, Gómez, HL, Prat, A, Moreno, F, Jerez-Gilarranz, Y, Barnadas, A, Picornell, AC, Monte-Millán MD, González-Rivera, M, Massarrah, T, Pelaez-Lorenzo, B, Palomero, MI, González Del Val, R, Cortés, J, Fuentes-Rivera H, Morales, DB, Márquez-Rodas, I, Perou, CM, Lehn, C, Wang, YY, Klemp, JR, Mammen, JV, Wagner, JL, Amin, AL, O'Dea, AP, Heldstab, J, Jensen, RA, Kimler, BF, Godwin, AK, Martín, M

Publicado 2018

Enlace

Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...

artículo

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Publicado por
Martín, M, Stecklein, SR, Gluz, O, Villacampa, G, Monte-Millán, M, Nitz, U, Cobo, S, Christgen, M, Brasó-Maristany, F, Álvarez, EL, Echavarría, I, Conte, B, Kuemmel, S, Bueno-Muiño, C, Jerez, Y, Kates, R, Cebollero, M, Kolberg-Liedtke, C, Bueno, O, García-Saenz, JÁ, Moreno, F, Grischke, E-M, Forstbauer, H, Braun, M, Warm, M, Hackmann, J, Uleer, C, Aktas, B, Schumacher, C, Wuerstleins, R, Graeser, M, zu, Eulenburg, C, Kreipe, HH, Gómez, H, Massarrah, T, Herrero, B, Paré, L, Bohn, U, López-Tarruella, S, Vivancos, A, Sanfeliu, E, Parker, JS, Perou, CM, Villagrasa, P, Prat, A, Sharma, P, Harbeck, N

Publicado 2024

Enlace

Background: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts. Methods: Information from 1259 patients with early-stage TNBC (SCAN-B, CALGB-40603, and BrighTNess) was used to establish the TNBC-DX scores. Independent validation of TNBC-DX was carried out in three studies: (i) WSG-ADAPT-TN; (ii) MMJ-CAR-2014-01; and (iii) NeoPACT, including 527 patients with stage I-III TNBC undergoing neoadjuvant chemotherapy. In...